Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAT2A | P31153 | 7/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355198 | 0.88 | TACR1 (0.39) | CYP1A2CYP2D6MAT2APRMT5NTRK1 | |
| SCHEMBL5101582 | 0.84 | MAT2A (0.39) | MAT2APRMT5NTRK1RXRA | |
| SCHEMBL5089907 | 0.84 | HTR6 (0.44) | CYP1A2CYP2D6MAT2AHTR6NTRK1 | |
| SCHEMBL5095637 | 0.78 | HTR6 (0.57) | SLC6A4HTR6RXRA | |
| SCHEMBL5094719 | 0.75 | TACR1 (0.52) | SLC6A4HTR6RXRARAD52 | |
| SCHEMBL5101584 | 0.75 | NTRK1 (0.40) | CYP1A2MAT2APRMT5NTRK1 | |
| SCHEMBL5767358 | 0.74 | MAT2A (0.41) | MAT2ASLC6A4HTR6RXRARAD52 | |
| SCHEMBL5101426 | 0.74 | HTR6 (0.40) | CYP1A2CYP2D6MAT2AHTR6RXRA | |
| SCHEMBL5101367 | 0.72 | HTR6 (0.40) | CYP1A2MAT2ASLC6A4HTR6RXRA | |
| SCHEMBL5094690 | 0.72 | HTR6 (0.44) | HTR6MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317035-B2 | Tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2008-01-08 | — | — | US | disclosed |
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | TPH1, HTR1A, HTR5A | CYP1A2 277/4885CYP2D6 118/4885MAT2A 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.